157286-82-3Relevant academic research and scientific papers
Pyrrolopyrimidines as CRF antagonists
-
, (2008/06/13)
The compounds of the formula wherein R1, R2, R3, R4, R5and R6are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.
Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
-
Page column 17, (2010/02/05)
Disclosed are compounds of the formula: wherein Ar is optionally substituted aryl or heteroaryl R1is hydrogen or alkyl; R7is hydrogen or alkyl; R2is hydrogen, halogen, alkyl or alkoxy; or R1and R2taken together with the ring to which they are attached form a 5-9 membered saturated or aromatic ring optionally having a hetero atom selected from oxygen, sulfur or nitrogen; R3and R4are independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl groups; or R3and R4together with the nitrogen atom to which they are attached form a 5-8 membered ring; and R5is hydrogen, halogen, straight or branched chain lower alkyl having 1-6 carbon atoms, or straight or branched chain lower alkoxy or thioalkoxy having 1-6 carbon atoms, which compounds are highly selective partial agonists or antagonists at human Corticotropin-Releasing Factor 1 (CRF1) receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post trumatic stress disorder (PTSD) as well as depression, headache and anxiety.
